MAB5212
Anti-Neurocan Antibody, clone 650.24
clone 650.24, Chemicon®, from mouse
Synonym(s):
245 kDa Early Postnatal Core Glycoprotein
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
650.24, monoclonal
species reactivity
rat
manufacturer/tradename
Chemicon®
technique(s)
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... NCAN(1463)
General description
Neurocan is the major soluble chondroitin sulfate proteoglycan in the brain. It is thought to play a functional role in axonal growth and guidance and in the establishment of specific neural pathways during embryonic brain development. Neurocan expression in the brain is developmentally regulated. Early on the major form of neurocan consists of a 245 kD core protein with approximately two chondroitin sulfate glycosoaminoglycan chains of 22 kD each. Later neurocan comprises a 180 kD core protein. Both forms of neurocan contain only chondroitin 4-sulfate glycosoaminoglycan chains. By virtue of their high expression at sites of neurnal damage and trauma, chondroitin sulfate proteoglycans, including neurocan, are thought to inhibit successful nerve regeneration.
Specificity
Neurocan. The specificity of clone 650.24 was checked by western blots of brain lysates and purified neurocan; the antibody reacted with the identical bands that clones 1D1 and 1F6 (other neurocan monoclonals) reacted; furthermore, the staining pattern of brain sections with these antibodies were all identical. Finally 650.24 also recognized recombinant neurocan expressed in transfected 293 cells by western blot.
Immunogen
Embryonic rat brain proteoglycans
Application
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neuroregenerative Medicine
Growth Cones & Axon Guidance
Neuroregenerative Medicine
Growth Cones & Axon Guidance
This Anti-Neurocan Antibody, clone 650.24 is validated for use in IP, WB, IC, IH for the detection of Neurocan.
Western blot: 1-2 μg/mL. Reacts with polypeptides of 260 and 160 kDa on western blots of embryonic rat brain tissue extracts. The 160 kDa species is typically only seen aftyer chondroitinase treatment.Treatment is at a concentration of chondroitinase of 10U/mL in Tris-HCL pH 8.0. Make tissue or cell extract in 20-50mM Tris pH 7.6-8.0 with 0.15M NaCl in the presence of protease inhibitors. Add 1 microliter of enzyme to 30 microliters of extract and incubate 30 minutes at 37C. Then add SDS sample buffer, heat or boil sample as normal for SDS reducing samples.
Immunocytochemistry: 1:5
Immunohistochemistry on 4% paraformaldehyde fixed tissue: 1:1,000
Immunoprecipitation: 1-2 μg/mL
Optimal working dilutions must be determined by the end user.
Immunocytochemistry: 1:5
Immunohistochemistry on 4% paraformaldehyde fixed tissue: 1:1,000
Immunoprecipitation: 1-2 μg/mL
Optimal working dilutions must be determined by the end user.
Physical form
Format: Purified
Purified immunoglobulin. Liquid in 0.02M Phosphate buffer, 0.25M NaCl with 0.1% sodium azide.
Storage and Stability
Maintain at 2-8°C in undiluted aliquots for up to 6 months.
Analysis Note
Control
POSITIVE CONTROL:
early post-natal rat brain. Not expressed in kidney, lung, liver, or muscle.
POSITIVE CONTROL:
early post-natal rat brain. Not expressed in kidney, lung, liver, or muscle.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Alterations in chondroitin sulfate proteoglycan expression occur both at and far from the site of spinal contusion injury.
Andrews, EM; Richards, RJ; Yin, FQ; Viapiano, MS; Jakeman, LB
Experimental neurology null
Marc R Del Bigio et al.
Cerebrospinal fluid research, 5, 12-12 (2008-07-12)
The cerebral cortex may be compressed in hydrocephalus and some experiments suggest that movement of extracellular substances through the cortex is impaired. We hypothesized that the extracellular compartment is reduced in size and that the composition of the extracellular compartment
James M Massey et al.
Experimental neurology, 209(2), 426-445 (2007-06-02)
Increased chondroitin sulfate proteoglycan (CSPG) expression in the vicinity of a spinal cord injury (SCI) is a primary participant in axonal regeneration failure. However, the presence of similar increases of CSPG expression in denervated synaptic targets well away from the
Frauke Seehusen et al.
PloS one, 11(7), e0159752-e0159752 (2016-07-22)
In demyelinating diseases, changes in the quality and quantity of the extracellular matrix (ECM) may contribute to demyelination and failure of myelin repair and axonal sprouting, especially in chronic lesions. To characterize changes in the ECM in canine distemper demyelinating
Wu-Fu Chen et al.
CNS neuroscience & therapeutics, 21(9), 698-707 (2015-07-21)
To date, no reliable methods have proven effective for treating spinal cord injury (SCI). Even systemic administration of methylprednisolone (MP) remains controversial. We previously reported that intrathecal (i.t.) administration of granulocyte colony-stimulating factor (G-CSF) improves outcome after experimental spinal cord
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service